[Topical formulation of doxepin and ex vivo evaluation of drug percutaneous absorption in atopic dermatitis]

ABSTRACT

Introduction and Objective: atopic dermatitis [AD] is a chronic and inflammatory skin disorder characterized by erythematous, eczematous, and highly pruritic lesions. Topical corticosteroids and oral antihistamines such as hydroxyzine, diphenhydramine, and promethazine are useful for the control of pruritus. Doxepin, a tricyclic antidepressant, with potent H1, H2 and muscarinic receptor blocking activity has recently been licensed as a topical treatment [Zonalon® 5% cream] by the Food and Drug Administration [FDA] for the short term [up to 8 days] management of moderate pruritus in adults with atopic dermatitis and lichen simplex chronicus. The objective of this investigation was to evaluate the physicochemical stability of various dermatological preparations of doxepin. Furthermore, the Ex-vivo percutaneous absorption of drug profiles obtained from different formulations was compared